MedTrace Logo

A TQT Study to Evaluate the Electrocardiographic Effects of Carbidopa in Healthy Subjects

NCT06161220 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2024-03-05

No results posted yet for this study

Summary

The purpose of this trial is to assess the effects of a single supratherapeutic dose of carbidopa on cardiac repolarization relative to placebo in healthy adult subjects.

Conditions

  • Cardiac Repolarization in Healthy Subjects

Interventions

DRUG

Carbidopa capsule

Dose: 4x 100 mg

DRUG

Moxifloxacin Tablets, USP

Dose: 400 mg

DRUG

Placebo

Placebo capsules matching the carbidopa capsules

Sponsors & Collaborators

  • Impax Laboratories, LLC

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-10-30
Primary Completion
2023-12-03
Completion
2023-12-05
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06161220 on ClinicalTrials.gov